Galapagos NV (AMS:GLPG)
Netherlands · Delayed Price · Currency is EUR | Market Cap | 1.89B |
| Revenue (ttm) | 275.61M |
| Net Income (ttm) | -284.27M |
| Shares Out | 65.90M |
| EPS (ttm) | -4.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 65,005 |
| Average Volume | 101,758 |
| Open | 28.82 |
| Previous Close | 29.56 |
| Day's Range | 28.60 - 29.26 |
| 52-Week Range | 20.00 - 32.74 |
| Beta | 0.06 |
| RSI | 50.24 |
| Earnings Date | Nov 5, 2025 |
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ... [Read more]
Financial Performance
In 2024, Galapagos NV's revenue was 275.65 million, an increase of 14.99% compared to the previous year's 239.72 million. Earnings were 74.08 million, a decrease of -65.01%.
Financial StatementsNews
Galapagos Receives Non-Binding Offers For Cell Therapy Business
(RTTNews) - Galapagos NV (GLPG) said that it has received a limited number of non-binding offers from consortia—primarily composed of financial investors—expressing interest in acquiring the company's...
Galapagos (GLPG) Explores Strategic Alternatives for Cell Therapy Division
Galapagos (GLPG) Explores Strategic Alternatives for Cell Therapy Division
Galapagos (GLPG) Considers Strategic Options for Cell Therapy Unit
Galapagos (GLPG) Considers Strategic Options for Cell Therapy Unit
Galapagos updates on strategic alternatives for cell therapy business
Galapagos (GLPG) explores strategic options for its Cell Therapy Business, including divestiture, to boost shareholder value.
Biotechnology firm Galapagos receives offers for cell-therapy business
Biotechnology firm Galapagos' board has received non-binding offers from consortia, mainly comprised of financial investors, for its cell-therapy business, the company said on Wednesday.
Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business
Mechelen, Belgium ; October 1, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and its Board of Directors today issued the following statement:
Galapagos Creates New Subscription Right Plan
Mechelen, Belgium; August 7, 2025, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,800,000 subscription rights under a ...
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration (FD...
Galapagos reports 1H results
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation
Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-te...
Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors
New Directors bring deep commercial, operational, and transaction experience to the Board Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appoin...
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update
Appointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic transactions will position the Company to drive shareholder value and advance p...
Galapagos Q2 2025 Earnings Preview
Galapagos appoints Aaron Cox as CFO
Galapagos Appoints Aaron Cox as Chief Financial Officer
Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven days of manufacturing
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL
Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin's Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities
Galapagos Creates New Subscription Right Plan
Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new...
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes
Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments
Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101
Galapagos reported promising results from ATALANTA-1 study show 100% ORR/CR for relapsed Mantle Cell Lymphoma. Click for GLPG stock prospects post Q1 earnings.
Galapagos NV outlines plans for pivotal CAR-T trials and SpinCo separation in 2025
Galapagos NV (GLPG) Q1 2025 Earnings Call Transcript
Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts
First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal developme...
Uncovering Potential: Galapagos's Earnings Preview
Galapagos (NASDAQ: GLPG) will release its quarterly earnings report on Wednesday, 2025-04-23. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Galapagos to report ...